PainReform Ltd. (PRFX): Price and Financial Metrics
PRFX Price/Volume Stats
| Current price | $0.85 | 52-week high | $26.41 |
| Prev. close | $0.89 | 52-week low | $0.69 |
| Day low | $0.77 | Volume | 6,652 |
| Day high | $0.86 | Avg. volume | 118,620 |
| 50-day MA | $1.72 | Dividend yield | N/A |
| 200-day MA | $3.21 | Market Cap | 1.73M |
PRFX Stock Price Chart Interactive Chart >
PainReform Ltd. (PRFX) Company Bio
PainReform Ltd. operates as a pharmaceutical company. It develops and markets pharmaceuticals. The firm focuses on developing reformulation of pain therapeutics, PainReform applies its propriety formulation technologies to prolong and enhance efficacy, reduce adverse effects shortening recovery time and reduce the need of augmentation with drugs such as opioids and NSAIDS. The company was founded by Lihu Avitov and Dan Teleman in 2007 and is headquartered in Herzliya, Israel.
Latest PRFX News From Around the Web
Below are the latest news stories about PAINREFORM LTD that investors may wish to consider to help them evaluate PRFX as an investment opportunity.
PainReform Provides Business Update for the Third Quarter of 2023Reports enrollment of first patients for the second part of Phase 3 clinical trial in bunionectomyTEL AVIV, Israel, Nov. 15, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided a business update for the third quarter ended September 30, 2023. Ilan Hadar, Chief Executive Officer of PainReform, stated, "We are pleased to report a number of |
PainReform Announces Plans to Commence Second Part of Phase 3 Clinical Trial to Evaluate PRF-110 in Patients Undergoing Bunionectomy Surgery Following Positive FDA Review of Drug Master FileTargeting to commence second part of Phase 3 clinical trial in mid-Q4 2023 Trial completion and results expected in mid-2024 TEL AVIV, Israel, Sept. 11, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced plans to commence the second part of the Company’s phase 3 trial to evaluate PRF-110 in patients undergoing bunionectomy surgery. Star |
PainReform Selected for Poster Presentation at the 13th Congress of the European Pain Federation in Budapest, HungaryProfessor Eli Hazum to Share Positive Safety and PK Data of PRF-110 from First Part of Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy SurgeryTEL AVIV, Israel, Sept. 07, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that Company has been selected for a poster presentation, titled “Pharmacokinetics and Safety P |
PainReform to Participate in the H.C. Wainwright 25th Annual Global Investment Conference in New York CityTEL AVIV, Israel, Sept. 05, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that Ilan Hadar, Chief Executive Officer of PainReform will be attending the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023 at the Lotte New York Palace Hotel in New York City. Mr. Hadar will be participating in one- |
7 Stocks Under $10 to Buy for AugustStocks under $10 have many advantages, so it pays to see which has the best potential for growth. |
PRFX Price Returns
| 1-mo | -52.78% |
| 3-mo | -58.13% |
| 6-mo | -62.55% |
| 1-year | -84.96% |
| 3-year | -97.44% |
| 5-year | N/A |
| YTD | -69.09% |
| 2023 | -33.37% |
| 2022 | -68.97% |
| 2021 | -70.25% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...